A cost utility model of interferon beta-1b in the treatment of relapsing-remitting multiple sclerosis

Abstract

This study estimates the long-term cost effectiveness of Betaferon®, (interferon beta-1b) in the treatment of relapsing-remitting multiple sclerosis (RRMS). Clinical trial data, natural disease history information, and costs and quality of life (EQ-5D) data, are linked using disease severity levels, via a model that accounts for the number, severity and duration of relapses, and the probability and speed of disease progression. Previous attempts at modelling the cost effectiveness of beta interferon have produced very high estimates of costs per QALY gained (CQG). Increasing data availability enables the modification or replacement of many of the assumptions underlying these models. In particular, longer term modelling and the consideration of wider societal costs is appropriate in the context of this chronic disease. The evidence presented here provides much lower, and more precise, estimates of CQG. The base case 20-year model estimates a CQG of £8,100. These new estimates are in line with other recent estimates and demonstrate the cost effectiveness of beta interferon.